Renaissance Capital logo

Loxo Oncology Priced, Nasdaq: LOXO

Early-stage biotech developing targeted therapies to treat solid tumors.

Industry: Health Care

First Day Return: 0.0%

Early-stage biotech developing targeted therapies to treat solid tumors.

Loxo Oncology (LOXO) Performance

Created with Highcharts 10.3.2Chart context menuLOXO vs. IPO Index (IPOUSA)20152016201720182019202020212022202320242025-100%0%+ 100%+ 200%+ 300%View 5 days5dView 1 month1mView 3 months3mView year to dateYTDView 1 year1yView allAllRenaissance IPO IndexOur ETF tracks the IPO Index